FDA Submission Update for OPDIVO (Nivolumab) by Bristol Myers Squibb
Bristol Myers Squibb has submitted a supplemental application for OPDIVO (Nivolumab) under BLA125554, currently under standard review.
Asset / Drug
Drug and asset intelligence for OPDIVO (Nivolumab) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
PD-1 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.